Page last updated: 2024-08-24

triazoles and decitabine

triazoles has been researched along with decitabine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Steensma, DP; Tefferi, A1
Allen, PB; Baer, MR; Kleinberg, ME; Koka, R1
Bhatnagar, B; Blum, W; Devine, S; Garzon, R; Hofstetter, J; Kauffman, M; Klisovic, R; Marcucci, G; Phelps, MA; Ranganathan, P; Santhanam, R; Shacham, S; Vasu, S; Walker, A; Walsh, K; Yu, X1
Chen, Q; Gu, J; Li, N; Li, S; Wang, W; Wang, X; Wang, Z; Zhao, G1
Estey, EH; Percival, MM1
Bugide, S; Green, MR; Gupta, R; Wajapeyee, N1

Reviews

2 review(s) available for triazoles and decitabine

ArticleYear
Risk-based management of myelodysplastic syndrome.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:1

    Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles

2007
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
    Cancer, 2019, Sep-15, Volume: 125, Issue:18

    Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles

2019

Other Studies

4 other study(ies) available for triazoles and decitabine

ArticleYear
Scedosporium apiospermum soft tissue infection as the initial presentation of acute myeloid leukemia: a case report.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Mar-01, Volume: 31, Issue:7

    Topics: Aged, 80 and over; Amputation, Surgical; Antifungal Agents; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Diagnosis, Differential; Disease Progression; Fatal Outcome; Female; Humans; Leg Ulcer; Leukemia, Myeloid, Acute; Mycoses; Pancytopenia; Pyrimidines; Scedosporium; Soft Tissue Infections; Triazoles; Voriconazole

2013
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
    Blood, 2015, Apr-23, Volume: 125, Issue:17

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; DNA Modification Methylases; Exportin 1 Protein; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Cells, Cultured; Up-Regulation

2015
Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
    Oncotarget, 2017, May-30, Volume: 8, Issue:22

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzoates; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Decitabine; Deferasirox; Drug Synergism; Gene Expression Regulation; Humans; Iron Chelating Agents; Leukemia; Reactive Oxygen Species; Triazoles

2017
EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.
    Proceedings of the National Academy of Sciences of the United States of America, 2021, 07-27, Volume: 118, Issue:30

    Topics: Animals; Benzopyrans; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Chemokine CXCL10; Chemokines; Decitabine; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Indazoles; Indoles; Killer Cells, Natural; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Phenols; Pyridones; Sulfones; Triazoles

2021